101650-17-3

Basic information

• Product Name: (S)-(+)-2-AMINO-4-BROMOBUTYRIC ACID METHYL ESTER
• Synonyms: (S)-(+)-2-AMINO-4-BROMOBUTYRIC ACID METHYL ESTER;METHYL (S)-2-AMINO-4-BROMOBUTYRATE HBR;Methyl(S)-2-amino-4-bromobutyrate;Methyl (S)-2-amino-4-bromobutyrate hydrobromide;(2S)-2-bromo-Butanoicacidmethylester
• CAS NO: 101650-17-3
• Molecular Formula: C₅H₁₀BrNO₂
• Molecular Weight: 196.04
• Product Categories: pharmacetical
• Mol File: 101650-17-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 250.7°Cat760mmHg
• Flash Point: 105.4°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 0.0148mmHg at 25°C
• CAS DataBase Reference: (S)-(+)-2-AMINO-4-BROMOBUTYRIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(+)-2-AMINO-4-BROMOBUTYRIC ACID METHYL ESTER(101650-17-3)
• EPA Substance Registry System: (S)-(+)-2-AMINO-4-BROMOBUTYRIC ACID METHYL ESTER(101650-17-3)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 101650-17-3(Hazardous Substances Data)

Usage

General Description

(S)-(+)-2-AMINO-4-BROMOBUTYRIC ACID METHYL ESTER is a chemical compound with the molecular formula C5H10BrNO2. It is a methyl ester derivative of the amino acid 2-amino-4-bromobutyric acid. (S)-(+)-2-AMINO-4-BROMOBUTYRIC ACID METHYL ESTER is primarily used in the field of organic synthesis and medicinal chemistry as a building block for the preparation of various biologically active compounds. It has potential applications in the development of pharmaceuticals, agrochemicals, and materials science. Additionally, it may also be used as a chiral auxiliary in asymmetric synthesis and as a reagent in chemical reactions.

InChI:InChI=1/C5H10BrNO2.BrH/c1-9-5(8)4(7)2-3-6;/h4H,2-3,7H2,1H3;1H/t4-;/m0./s1

Upstream product

• 67-56-1 methanol 
• 15159-65-6 (2S)-2-amino-4-bromobutanoic acid hydrobromide 

Downstream Products

• 875668-08-9 methyl (2S)-4-bromo-2-N-[4-(N-benzyloxycarbonyl-N-methyl)aminobenzoyl]aminobutyrate 
• 15159-67-8 (2S)-2-benzyloxycarbonylamino-4-bromo-butyric acid methyl ester 
• 92136-57-7 (S)-2-tert-butoxycarbonylamino-hex-5-enoic acid methyl ester 
• 87974-77-4 methyl (2S)-2-tert-butoxycarbonylaminohexanoate 
• 64896-37-3 methyl N-{[(1,1-dimethylethyl)oxy]carbonyl}-L-norvalinate 
• 359781-97-8 methyl 4-azido-2S-{[(1,1-dimethylethoxy)carbonyl]amino}butyrate 
• 101650-14-0 methyl (2S)-2-(tert-butoxycarbonyl)amino-4-iodobutanoate 
• 875668-19-2 methyl (2S)-2-N-[4-(N-carbobenzyloxy-N-methyl)aminobenzoyl]amino-4-(phenylselenyl)butyrate 
• 76969-87-4 methyl (2S)-4-bromo-2-[(tert-butoxycarbonyl)amino]butanoate 

Relevant articles and documents

Optimal linker length for small molecule PROTACs that selectively target p38α and p38β for degradation

We report the design of hetero-bifunctional small molecules that selectively target p38α and p38β for degradation. These proteolysis targeted chimeras (PROTACs) are based on an ATP competitive inhibitor of p38α and p38β, which is linked to thalidomide analogues to recruit the Cereblon E3 ubiquitin ligase complex. Compound synthesis was facilitated by the use of a copper catalyzed “click” reaction. We show that optimization of the linker length and composition is crucial for the degradation-inducing activity of these PROTACs. We provide evidence that these chemical compounds can induce degradation of p38α and p38β but no other related kinases at nanomolar concentrations in several mammalian cell lines. Accordingly, the PROTACs inhibit stress and cytokine-induced p38α signaling. Our compounds contribute to understanding the development of PROTACs, and provide a useful tool to investigate functions of the p38 MAPK pathway and its involvement in diseases.

SUBSTITUTED 2-PHENYL-PYRIDINE DERIVATIVES

The present invention relates to compounds of formula I wherein R1, R2, R4, R5, Ra, Rb, n, W and Z are as defined in the application, their preparation and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

Prodrug forms of N-[(4-deoxy-4-amino-10-methyl)pteroyl]glutamate-γ- [ψP(O)(OH)]-glutarate, a potent inhibitor of folylpoly-γ-glutamate synthetase: Synthesis and hydrolytic stability

Ester prodrugs of the phosphinate pseudopeptide N-[(4-deoxy-4-amino-10- methyl)pteroyl]glutamate-γ-[ψP-(O)(OH)]-glutarate (1a) were synthesized. H-phosphinic acids derived from N-Cbz vinyl glycine esters were converted to the desired pseudopeptides by Michael addition to α-methyleneglutarate esters. Pivaloyloxymethyl (POM) ester moieties were incorporated in both the N-terminal and C-terminal fragments prior to formation of either C-P bond, N-Alkylation of the corresponding amides derived from N-(N-methyl)aminobenzoic acid with 2,4-diamino-6-(bromomethyl)pteridine gave the target compounds. POM esters of methotrexate and the corresponding γ-glutamyl conjugate were also synthesized using the same strategy. All prodrugs were evaluated in Chinese hamster ovary cells. Although the pseudopeptide prodrugs were ineffective, prodrugs of methotrexate and the corresponding γ-glutamyl conjugate were equipotent with the parent compounds. Stability of the prodrugs was investigated in both phosphate buffer and cell line medium to provide a rationale for the observed biological data.